Long-term safety of oral MS therapies: two reports


REPORT FROM THE 25TH CONGRESS OF THE EUROPEAN COMMITTEE FOR TREATMENT AND RESEARCH IN MULTIPLE SCLEROSIS (ECTRIMS) – AMSTERDAM, THE NETHERLANDS, OCTOBER 19-22, 2011 – Data from phase II extension studies of fingolimod and teriflunomide indicate that long-term treatment with an oral MS therapy appears safe, with no new safety signals during the observation period.

It takes 30 seconds

Recommend to a Colleague

Related Posts

Go back to home page